28 results on '"P. St. George-Hyslop"'
Search Results
2. LRRK2 gene in Parkinson disease: Mutation analysis and case control association study
- Author
-
T. Kawarai, Anthony E. Lang, T. Al-Khairallah, Christine Sato, G. K. Fisman, Shabnam Salehi-Rad, Coro Paisán-Ruiz, Ekaterina Rogaeva, P. St. George-Hyslop, and Amanda Singleton
- Subjects
Adult ,Proband ,Genotype ,DNA Mutational Analysis ,Protein Serine-Threonine Kinases ,Biology ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,medicine.disease_cause ,Parkin ,Apolipoproteins E ,Gene Frequency ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Age of Onset ,Allele ,Family history ,Aged ,Aged, 80 and over ,Family Health ,Genetics ,Mutation ,Polymorphism, Genetic ,Case-control study ,Parkinson Disease ,Exons ,Middle Aged ,LRRK2 ,nervous system diseases ,Case-Control Studies ,Neurology (clinical) - Abstract
Background: In addition to the four well-confirmed genes linked to early-onset Parkinson disease (PD) (SNCA, PARKIN, DJ-1, and PINK1), mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have recently been identified in families with autosomal dominant late-onset PD. Objective: To perform mutation analysis of LRRK2 in probands of families showing dominant inheritance of PD and to conduct a case control association study to test the hypothesis that common coding variations might be associated with increased susceptibility to PD. Methods: All 51 LRRK2 coding exons were sequenced in 23 probands and the mutation frequencies were evaluated in 180 neurologically normal control subjects. For the association study the authors genotyped four coding LRRK2 polymorphisms in 250 normal control subjects and 121 patients with PD (predominantly white patients of Canadian origin), 84% of whom had age at onset before 50 years and 42% had a positive family history. Results: The authors identified three probands with heterozygous LRRK2 mutations: two of them have the known G2019S substitution and one proband has a novel I1371V substitution. Mutation analysis of a large family demonstrated complete segregation of the G2019S with PD. However, there was no association between PD and any of the four polymorphisms at the allelic or genotypic levels (p > 0.17). Furthermore, the authors did not detect a modifying effect for any genotype or of APOE genotypes upon the age at onset in the PD group (p > 0.20). Conclusions: The results support the prior suggestion that LRRK2 mutations cause PD. The disease in the families reported here presents a phenotype indistinguishable from typical PD. All three families demonstrate a very variable age at onset that is not explained by APOE genotypes. The common coding variations in the LRRK2 gene neither constitute strong PD risk factors nor modify the age at onset; however, the possibility of a modest risk effect remains to be assessed in large datasets.
- Published
- 2005
- Full Text
- View/download PDF
3. Familial Alzheimer disease: Decreases in CSF A 42 levels precede cognitive decline
- Author
-
M. P. E. Dayaw, Daniel A. Pollen, T. Kawarai, Joan M. Swearer, P. St. George-Hyslop, Majaz Moonis, and Ekaterina Rogaeva
- Subjects
Adult ,Male ,Heterozygote ,Pathology ,medicine.medical_specialty ,Amyloid ,DNA Mutational Analysis ,Down-Regulation ,tau Proteins ,Central nervous system disease ,Cerebrospinal fluid ,Degenerative disease ,Alzheimer Disease ,Predictive Value of Tests ,Presenilin-1 ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Cognitive decline ,Family Health ,Window of opportunity ,Amyloid beta-Peptides ,Cognitive disorder ,Brain ,Membrane Proteins ,Middle Aged ,medicine.disease ,Peptide Fragments ,Mutation ,Immunology ,Disease Progression ,Female ,Neurology (clinical) ,Alzheimer's disease ,Cognition Disorders ,Psychology - Abstract
CSF amyloid beta-peptide 42 (Abeta42) levels in presymptomatic subjects with pathogenic mutations in the PS1 gene are significantly lower than in an age-matched control group. Consequently, in these subjects, there is a window of opportunity estimated as at least 4 to 12 years to evaluate the ability of any putative prophylactic therapy to decrease, arrest, or reverse abnormalities in Abeta42 metabolism many years before clinical symptoms of Alzheimer disease are otherwise likely to occur.
- Published
- 2005
- Full Text
- View/download PDF
4. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study
- Author
-
Mary C. Tierney, E. Dunn, P. St. George-Hyslop, A. Nores, W. G. Snow, G. Nadon, R. H. Fisher, and John P. Szalai
- Subjects
medicine.medical_specialty ,Wechsler Memory Scale ,Longitudinal study ,Neuropsychological Tests ,Audiology ,Logistic regression ,Sensitivity and Specificity ,Developmental psychology ,Alzheimer Disease ,Predictive Value of Tests ,medicine ,Humans ,Dementia ,Memory disorder ,Longitudinal Studies ,Prospective Studies ,Memory Disorders ,medicine.diagnostic_test ,Neuropsychological test ,medicine.disease ,Predictive value of tests ,Regression Analysis ,Neurology (clinical) ,Alzheimer's disease ,Psychology ,Forecasting - Abstract
We determined whether a battery of neuropsychological tests could predict who would develop Alzheimer's disease (AD) in a group of 123 memory-impaired nondemented patients. Patients were followed longitudinally for 2 years with a research battery of neuropsychological tests. After 2 years, 29 developed probable AD, and 94 did not develop dementia. We used logistic regression analyses to examine the classification accuracy of subjects' performance at entry to the study on the research battery. The logistic regression model was significant with an accuracy of 89%, sensitivity of 76%, and specificity of 94%. Two tests contributed significantly to this model: the delayed recall from the Rey Auditory Verbal Learning Test and the Mental Control subtest of the Wechsler Memory Scale. These two tests alone produced the same accuracy, sensitivity, and specificity as the larger model. These results demonstrate that probable AD can be predicted with a high degree of accuracy and with a relatively brief battery of neuropsychological tests.
- Published
- 1996
- Full Text
- View/download PDF
5. PS1 Alzheimer's disease family with spastic paraplegia: The search for a gene modifier
- Author
-
T Kolesnikova, Antonio Orlacchio, P. St. George-Hyslop, T. Kawarai, Christine Sato, You-Qiang Song, I Moliaka, Catherine Bergeron, Giorgio Bernardi, Anna Toulina, and Ekaterina Rogaeva
- Subjects
Male ,Pathology ,DNA Mutational Analysis ,Plaque, Amyloid ,Chromosome Disorders ,GTP Phosphohydrolases ,Degenerative disease ,Polymorphism (computer science) ,Spastic ,Alternative Splicing ,Alzheimer Disease ,Brain ,Female ,GTP-Binding Proteins ,Genes, Dominant ,Humans ,Membrane Proteins ,Middle Aged ,Mutation ,Paraplegia ,Pedigree ,Phenotype ,Polymorphism, Genetic ,Presenilin-1 ,Spinal Cord ,Family ,Plaque ,Genetics ,Mutation (genetic algorithm) ,Settore MED/26 - Neurologia ,Alzheimer's disease ,medicine.symptom ,Amyloid ,medicine.medical_specialty ,Presenilin ,Genetic determinism ,Genetic ,mental disorders ,medicine ,Dominant ,Spasticity ,Polymorphism ,business.industry ,medicine.disease ,nervous system diseases ,Genes ,Neurology (clinical) ,business - Abstract
PS1 mutations are associated with classic Alzheimer's disease (AD); however, some families develop AD and spastic paraplegia (SP) with brain pathology characterized by Abeta cotton wool plaques. The authors report a variant AD family with the E280Q PS1 mutation. The fact that the same PS1 mutation can be found in patients with either variant or classic AD argues in favor of the presence of a genetic modifier. The authors have excluded that this modifier effect originates from coding sequence variations in three SP genes or from a second mutation in the other AD genes.
- Published
- 2003
- Full Text
- View/download PDF
6. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation
- Author
-
John Hardy, Francesca Frangipane, Ekaterina Rogaeva, Silvana Geracitano, Gianfranco Puccio, Carmine Tomaino, Yosuke Wakutani, S. Pradella, Livia Bernardi, M. Anfossi, Amalia C. Bruni, Christine Sato, P. St. George-Hyslop, Parastoo Momeni, Rosanna Colao, Raffaele Maletta, T. Kawarai, Maria Mirabelli, Nicoletta Smirne, Andrew Kertesz, Joshua W. Elder, A. Costanzo, Sabrina A.M. Curcio, and Maura Gallo
- Subjects
Proband ,Adult ,Genetic Markers ,Male ,Heterozygote ,Genotype ,DNA Mutational Analysis ,Biology ,Cohort Studies ,Progranulins ,Gene Frequency ,mental disorders ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Allele ,Age of Onset ,Allele frequency ,Aged ,Phenocopy ,Genetics ,Aged, 80 and over ,Genetic heterogeneity ,Genetic Carrier Screening ,Haplotype ,Middle Aged ,medicine.disease ,Pedigree ,Italy ,Mutation (genetic algorithm) ,Mutation ,Intercellular Signaling Peptides and Proteins ,Dementia ,Female ,Neurology (clinical) ,Frontotemporal dementia ,Chromosomes, Human, Pair 17 - Abstract
Background: Frontotemporal dementia (FTD) in several 17q21-linked families was recently explained by truncating mutations in the progranulin gene ( GRN ). Objective: To determine the frequency of GRN mutations in a cohort of Caucasian patients with FTD without mutations in known FTD genes. Methods: GRN was sequenced in a series of 78 independent FTD patients including 23 familial subjects. A different Calabrian dataset (109 normal control subjects and 96 FTD patients) was used to establish the frequency of the GRN mutation. Results: A novel truncating GRN mutation (c.1145insA) was detected in a proband of an extended consanguineous Calabrian kindred. Segregation analysis of 70 family members revealed 19 heterozygous mutation carriers including 9 patients affected by FTD. The absence of homozygous carriers in a highly consanguineous kindred may indicate that the loss of both GRN alleles might lead to embryonic lethality. An extremely variable age at onset in the mutation carriers (more than five decades apart) is not explained by APOE genotypes or the H1/H2 MAPT haplotypes. Intriguingly, the mutation was excluded in four FTD patients belonging to branches with an autosomal dominant mode of inheritance of FTD, suggesting that another novel FTD gene accounts for the disease in the phenocopies. It is difficult to clinically distinguish phenocopies from GRN mutation carriers, except that language in mutation carriers was more severely compromised. Conclusion: The current results imply further genetic heterogeneity of frontotemporal dementia, as we detected only one GRN -linked family (about 1%). The value of discovering large kindred includes the possibility of a longitudinal study of GRN mutation carriers.
- Published
- 2007
7. A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI
- Author
-
Mitsuyasu Kanai, Masashi Aoki, P. St. George-Hyslop, M. Ikeda, Koji Abe, N. Oda, Yasuto Itoyama, Mikio Shoji, and T. Tsuda
- Subjects
Pathology ,medicine.medical_specialty ,Amyloid beta ,Gene mutation ,Presenilin ,White matter ,Exon ,Degenerative disease ,Alzheimer Disease ,mental disorders ,Presenilin-1 ,medicine ,Humans ,Point Mutation ,biology ,Brain ,Membrane Proteins ,DNA ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Pedigree ,medicine.anatomical_structure ,biology.protein ,Female ,Neurology (clinical) ,Alzheimer's disease ,medicine.symptom ,Myoclonus - Abstract
Some patients with familial Alzheimer's disease (FAD) have mutations in the presenilin-1 (PS-1) gene on chromosome 14. We report a Japanese family with AD and an Ala285Val substitution in exon 8 of the PS-1 gene. FAD in this family was characterized by relatively late onset (mean age, 50 years) and absence of myoclonus, seizures, or paratonia. Levels of tau were markedly elevated in CSF whereas CSF levels of amyloid beta protein were normal. MRI of the cranium showed marked linear signal abnormalities within white matter in the parieto-occipital lobes, consistent with cortical amyloid angiopathy of the type encountered in patients with the PS-1 gene mutation.
- Published
- 1997
- Full Text
- View/download PDF
8. A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics
- Author
-
Ranjan Duara, Dylan G. Harwood, Michael Mullan, Raymond L. Ownby, Warren W. Barker, David A. Loewenstein, and P. St. George-Hyslop
- Subjects
Gerontology ,Apolipoprotein E ,Male ,medicine.medical_specialty ,Population ,Ethnic group ,Degenerative disease ,Apolipoproteins E ,Alzheimer Disease ,Risk Factors ,Internal medicine ,Ethnicity ,Odds Ratio ,Medicine ,Humans ,Allele ,Risk factor ,education ,Alleles ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Odds ratio ,Hispanic or Latino ,medicine.disease ,Female ,Neurology (clinical) ,Alzheimer's disease ,business - Abstract
The prevalence of AD appears to vary widely in different ethnic groups. Certain risk factors for AD are well established for the general population, but there is little information regarding the relevance of these risk factors in specific ethnic groups.The authors examined the risk of AD associated with the APOE-epsilon4 allele, the APOE-epsilon2 allele, smoking, alcohol consumption, history of hypertension, low educational level, estrogen replacement therapy, and history of head trauma with loss of consciousness among samples of white non-Hispanics (WNH) (392 AD patients, 202 normal subjects) and white Hispanics (WHIS) (188 AD patients, 84 normal controls).This was a case-control study of patients evaluated at an outpatient memory disorders clinic and control subjects recruited from a free memory screening offered to the community.Increased risk for AD was associated with the APOE-epsilon4 allele after controlling for age, education, and gender among WNH (OR = 3.5; 95% CI = 2.3 to 5.5) and WHIS (OR = 3.1; 95% CI = 1.7 to 5.8). No protective effect was conferred by the APOE-epsilon2 allele, although this relationship approached significance among WNH (p = 0.02). Low levels of education increased the risk for AD among WNH (OR = 3.1; 95% CI = 1.8 to 5.9) but not WHIS. Alcohol use and hypertension approached significance as risk factors in WNH (p0.05) but not WHIS. Estrogen replacement treatment approached significance as a protective factor in both ethnic groups (p0.05).Although the APOE-epsilon4 allele is a risk factor for AD among WHIS and WNH, other risk factors such as low education and hypertension appear to be important only for WNH. Risk factors for AD reported or suggested previously that were not confirmed by this study include smoking and head trauma with loss of consciousness.
- Published
- 1999
9. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia
- Author
-
Mark Guttman, L. W. Morris, Yoshiaki Furukawa, Menachem Sadeh, Mitsunobu Shimadzu, T. Tagawa, Thomas D. Bird, P. St. George-Hyslop, O. Hornykiewicz, Stephen J. Kish, Joel M. Trugman, Anthony E. Lang, and A. Hunter
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,GTP cyclohydrolase I ,Nonsense mutation ,DNA Mutational Analysis ,Dopamine Agents ,Penetrance ,Biology ,Gene mutation ,medicine.disease_cause ,Levodopa ,Sex Factors ,Internal medicine ,medicine ,Humans ,Point Mutation ,Child ,GTP Cyclohydrolase ,Gene ,Aged ,Genes, Dominant ,Genetics ,Aged, 80 and over ,Family Health ,Mutation ,Point mutation ,Exons ,Middle Aged ,Introns ,Dystonia ,Endocrinology ,biology.protein ,Female ,Neurology (clinical) ,Genomic imprinting - Abstract
We evaluated the influence of gender on penetrance of GTP-cyclohydrolase I (GCH) gene mutations in hereditary progressive dystonia/dopa-responsive dystonia (HPD/DRD) and determined whether some apparently sporadic HPD/DRD patients owe their disorder to a de novo mutation of the GCH gene. Previous clinical investigations of HPD/DRD have shown a predominance of affected women, with approximately half of HPD/DRD patients being sporadic. We conducted genomic DNA sequencing of the GCH gene in five HPD/DRD families having at least two generations of affected members and in four apparently sporadic cases and all of their parents. In the nine HPD/DRD pedigrees, we found independent mutations of the GCH gene (five deletions, one insertion, one nonsense mutation, and two point mutations at splice acceptor sites). The female-to-male ratio of the HPD/DRD patients was 4.3 with the penetrance of GCH gene mutations in women being 2.3 times higher than that in men (87% versus 38%, p = 0.026). There was no significant difference in the penetrance between maternally and paternally transmitted offspring. All of the four sporadic cases had de novo mutations because none of their parents were carriers. The results demonstrate gender-related incomplete penetrance of GCH gene mutations in HPD/DRD and suggest that this may not be due to genomic imprinting. Our data also suggest a relatively high spontaneous mutation rate of the GCH gene in this autosomal dominant disorder.
- Published
- 1998
10. Fc Receptor Polymorphisms, Disease Severity and Response to IVIG Treatment in Myasthenia Gravis (S35.003)
- Author
-
C. Barnett Tapia, Y. Grinberg, M. Ghani, E. Rogaeva, P. St. George-Hyslop, H. Katzberg, and V. Bril
- Subjects
Neurology (clinical) - Published
- 2012
- Full Text
- View/download PDF
11. Transmission and age-at-onset patterns in familial Alzheimer's disease : evidence for heterogeneity
- Author
-
C. Van Broeckhoven, L. A. Cupples, Michael Mullan, John H. Growdon, Thomas D. Bird, J. J. Martin, D. Crapper-McLachlan, R. Polinsky, Linda Nee, Richard H. Myers, Leonard L. Heston, Lindsay A. Farrer, P. St. George-Hyslop, and Martin N. Rossor
- Subjects
Male ,Gerontology ,Genetic Linkage ,Offspring ,Disease ,Alzheimer Disease ,Risk Factors ,medicine ,Humans ,Dementia ,Survival analysis ,Aged ,Genes, Dominant ,Retrospective Studies ,Aged, 80 and over ,Models, Genetic ,business.industry ,Incidence (epidemiology) ,Age Factors ,Middle Aged ,medicine.disease ,Survival Analysis ,Pedigree ,Evaluation Studies as Topic ,Etiology ,Female ,Neurology (clinical) ,Human medicine ,Age of onset ,Alzheimer's disease ,business ,Demography - Abstract
We evaluated age at onset and lifetime risk for Alzheimer's disease (AD) in 70 kindreds with familial AD (designated FAD) composed of 541 affected and 1,066 unaffected offspring of demented parents who were identified retrospectively. Using a survival analysis method which takes into account affected persons with unknown onset ages and unaffected persons with unknown censoring ages, we found lifetime risk of AD among at-risk offspring by age 87 to be 64%. Analysis of age at onset among kindreds showed evidence for a bimodal distribution: in this sample, families with a mean onset age of less than 58 years were designated as having early-onset, while late-onset families had a mean onset age greater than 58 years. At-risk offspring in early-onset families had an estimated lifetime risk for dementia of 53%, which is significantly less than the risk of 86% that was estimated for offspring in late-onset families. Men and women in early-onset families had equivalent risk of dementia. In late-onset families, the risk to female offspring was somewhat higher than to male offspring but this difference was marginally significant. Lifetime risk of dementia in early-onset FAD kindreds is consistent with an autosomal dominant inheritance model. Our results may suggest that late-onset FAD has at least 2 etiologies; AD in some families may be transmitted as a dominant trait, whereas a proportion of cases in these and other late-onset families may be caused by other genetic or shared environmental factors.
- Published
- 1990
12. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
- Author
-
Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L, TODEM Study Group, Rubino, Elisa, Rainero, Innocenzo, Chiò, Adriano, and Rogaeva, Ekaterina
- Published
- 2012
- Full Text
- View/download PDF
13. Analysis of the c‐FOS gene on chromosome 14 and the promoter of the amyloid precursor protein gene in familial Alzheimer's disease
- Author
-
Ekaterina Rogaeva, Sandro Sorbi, Jonathan Haines, Evgeny I. Rogaev, Luigi Amaducci, Ranjan Duara, N. Alexandrova, D. Crapper MacLachlan, Innocenzo Rainero, P. St. George-Hyslop, G. Vaula, Amalia C. Bruni, James F. Gusella, Mp Montesi, Fabio Macciardi, L. Pinessi, T. Tsuda, R. J. Polinsky, M. Mortilla, Yan Liang, Daniel A. Pollen, Rudolph E. Tanzi, P. Frommelt, J. F. Foncin, Ramon Lopez, L. Bergamini, and Walter J. Lukiw
- Subjects
Adult ,APP gene ,amyloid precursor protein ,familial Alzheimer's disease ,Genetic Linkage ,Restriction Mapping ,Locus (genetics) ,Biology ,Gene product ,Amyloid beta-Protein Precursor ,Exon ,Alzheimer Disease ,Amyloid precursor protein ,Humans ,Promoter Regions, Genetic ,Gene ,Chromosomes, Human, Pair 14 ,Genetics ,Polymorphism, Genetic ,Nucleic acid sequence ,Genes, fos ,Middle Aged ,Pedigree ,Open reading frame ,biology.protein ,Neurology (clinical) ,Chromosome 21 - Abstract
The c-FOS gene product, a putative transacting transcriptional regulator of the amyloid precursor protein (APP) gene, is a candidate locus for the familial Alzheimer's disease (FAD) mutation on chromosome 14 (FAD14). In light of this functional relationship, we investigated the nucleotide sequence and segregation of c-FOS and the nucleotide sequence of the 5' APP promoter. Single-stranded conformational polymorphisms (SSCPs) in the c-FOS gene revealed that c-FOS closely cosegregates with the FAD14 gene but does not show allelic association with FAD. A conservative third-position T→C mutation was demonstrated in exon 2 (codon 84) of c-FOS, and a C→G substitution was detected at—209 bp in the 5' promoter of APP. Neither were unique to FAD and are unlikely to be pathogenic or secondary modifiers of the FAD phenotype. We conclude that the c-FOS open reading frame is probably not the site of the FAD14 locus, but we cannot exclude the existence of modifier loci on chromosome 21.
- Published
- 1993
- Full Text
- View/download PDF
14. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease
- Author
-
Margaret A. Pericak-Vance, B.L. Rosi, James F. Gusella, Warren J. Strittmatter, Donald E. Schmechel, D. R. Crapper-MacLachlan, Ann M. Saunders, A. D. Roses, Mark J. Alberts, Barbara J. Crain, S. H. Joo, Dmitry Goldgaber, Christine M. Hulette, and P. St. George-Hyslop
- Subjects
Male ,Apolipoprotein E ,medicine.medical_specialty ,Pathology ,SORL1 ,Pathogenesis ,Apolipoproteins E ,Degenerative disease ,Gene Frequency ,Alzheimer Disease ,Internal medicine ,PSEN2 ,medicine ,Humans ,Allele ,Allele frequency ,Alleles ,Aged ,Gene Amplification ,Middle Aged ,medicine.disease ,Endocrinology ,Mutation ,Female ,Neurology (clinical) ,Alzheimer's disease ,Psychology - Abstract
Apolipoprotein E, type epsilon 4 allele (APOE epsilon 4), is associated with late-onset familial Alzheimer's disease (AD). There is high avidity and specific binding of amyloid beta-peptide with the protein ApoE. To test the hypothesis that late-onset familial AD may represent the clustering of sporadic AD in families large enough to be studied, we extended the analyses of APOE alleles to several series of sporadic AD patients. APOE epsilon 4 is significantly associated with a series of probable sporadic AD patients (0.36 +/- 0.042, AD, versus 0.16 +/- 0.027, controls [allele frequency estimate +/- standard error], p = 0.00031). Spouse controls did not differ from CEPH grandparent controls from the Centre d'Etude du Polymorphisme Humain (CEPH) or from literature controls. A large combined series of autopsy-documented sporadic AD patients also demonstrated highly significant association with the APOE epsilon 4 allele (0.40 +/- 0.026, p < or = 0.00001). These data support the involvement of ApoE epsilon 4 in the pathogenesis of late-onset familial and sporadic AD. ApoE isoforms may play an important role in the metabolism of beta-peptide, and APOE epsilon 4 may operate as a susceptibility gene (risk factor) for the clinical expression of AD.
- Published
- 1993
- Full Text
- View/download PDF
15. Predictive testing for Wilson's disease using tightly linked and flanking DNA markers
- Author
-
P. St. George-Hyslop, Anne M. Bowcock, M. Giagheddu, Joan M. Hebert, Helen Donis-Keller, Lindsay A. Farrer, J. Lössner, Moshe Frydman, R. Lee, Carlo Carcassi, I. H. Scheinberg, R. Beker, Luigi Demelia, Luigi Luca Cavalli-Sforza, I. Sternlieb, Batsheva Bonne-Tamir, and Allen E. Bale
- Subjects
Genetic Markers ,Genetics ,Genotype ,Genetic Linkage ,Chromosome Mapping ,Locus (genetics) ,Biology ,medicine.disease ,Pedigree ,Wilson's disease ,Centimorgan ,Hepatolenticular Degeneration ,Predictive Value of Tests ,Genetic linkage ,Genetic marker ,Prenatal Diagnosis ,medicine ,Humans ,Neurology (clinical) ,Predictive testing ,Chromosome 13 - Abstract
We studied DNA polymorphisms for five new chromosome 13 markers in 52 Wilson's disease (WD) families from Europe, North America, and the Middle East. There was significant evidence for linkage between the Wilson's disease locus (WND) and all the marker loci. Multilocus linkage analysis, using a genetic linkage map established from reference pedigrees, suggested that WND is most likely between D13S31 and D13S59, at distances of 0.4 and 1.2 centimorgans, respectively. Our results suggest that the chromosomal location of the Wilson's disease gene is the same in all families from the populations studied. This evidence and the availability of many close, flanking, and polymorphic DNA markers make possible accurate and informative testing of potential carriers and WD homozygotes in families with at least one previously affected child. An advantage of a genetic linkage test over other laboratory methods for prediction of genotype in WD is that a reliable diagnosis can be made at a much earlier stage in life, including prenatally. In addition, DNA testing can be used in place of an invasive liver biopsy procedure to confirm a diagnosis in patients with borderline serum ceruloplasmin levels. Presymptomatic identification will also allow therapeutic intervention to prevent symptoms before irreparable liver or neurologic damage occurs. We describe the implementation of prenatal and preclinical diagnosis for two families with WD.
- Published
- 1991
- Full Text
- View/download PDF
16. APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia.
- Author
-
Mirza SS, Saeed U, Knight J, Ramirez J, Stuss DT, Keith J, Nestor SM, Yu D, Swardfager W, Rogaeva E, St George Hyslop P, Black SE, and Masellis M
- Subjects
- Aged, Aged, 80 and over, Alzheimer Disease diagnostic imaging, Alzheimer Disease genetics, Attention, Cognitive Dysfunction diagnostic imaging, Cognitive Dysfunction genetics, Executive Function, Factor Analysis, Statistical, Female, Humans, Language, Learning, Lewy Body Disease diagnostic imaging, Lewy Body Disease genetics, Linear Models, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Neuropsychological Tests, Alzheimer Disease psychology, Apolipoprotein E4 genetics, Cognitive Dysfunction psychology, Lewy Body Disease psychology, White Matter diagnostic imaging
- Abstract
Objective: To determine if APOE ε4 influences the association between white matter hyperintensities (WMH) and cognitive impairment in Alzheimer disease (AD) and dementia with Lewy bodies (DLB)., Methods: A total of 289 patients (AD = 239; DLB = 50) underwent volumetric MRI, neuropsychological testing, and APOE ε4 genotyping. Total WMH volumes were quantified. Neuropsychological test scores were included in a confirmatory factor analysis to identify cognitive domains encompassing attention/executive functions, learning/memory, and language, and factor scores for each domain were calculated per participant. After testing interactions between WMH and APOE ε4 in the full sample, we tested associations of WMH with factor scores using linear regression models in APOE ε4 carriers (n = 167) and noncarriers (n = 122). We hypothesized that greater WMH volume would relate to worse cognition more strongly in APOE ε4 carriers. Findings were replicated in 198 patients with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI-I), and estimates from both samples were meta-analyzed., Results: A significant interaction was observed between WMH and APOE ε4 for language, but not for memory or executive functions. Separate analyses in APOE ε4 carriers and noncarriers showed that greater WMH volume was associated with worse attention/executive functions, learning/memory, and language in APOE ε4 carriers only. In ADNI-I, greater WMH burden was associated with worse attention/executive functions and language in APOE ε4 carriers only. No significant associations were observed in noncarriers. Meta-analyses showed that greater WMH volume was associated with worse performance on all cognitive domains in APOE ε4 carriers only., Conclusion: APOE ε4 may influence the association between WMH and cognitive performance in AD and DLB., (Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2019
- Full Text
- View/download PDF
17. Novel late-onset Alzheimer disease loci variants associate with brain gene expression.
- Author
-
Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N, Apostolova LG, Arnold SE, Baldwin CT, Barber R, Barmada MM, Beach T, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buros J, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Crane PK, Cruchaga C, Cummings JL, De Jager PL, DeCarli C, DeKosky ST, Demirci FY, Diaz-Arrastia R, Dick M, Dombroski BA, Duara R, Ellis WD, Evans D, Faber KM, Fallon KB, Farlow MR, Ferris S, Foroud TM, Frosch M, Galasko DR, Gallins PJ, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Goate AM, Green RC, Growdon JH, Hakonarson H, Hamilton RL, Hardy J, Harrell LE, Head E, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh MI, Karlawish J, Karydas A, Kauwe JS, Kaye JA, Kennedy N, Kim R, Koo EH, Kowall NW, Kramer P, Kukull WA, Lah JJ, Larson EB, Levey AI, Lieberman AP, Lopez OL, Lunetta KL, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Myers AJ, Naj AC, Nowotny P, Parisi JE, Perl DP, Peskind E, Poon WW, Potter H, Quinn JF, Raj A, Rajbhandary RA, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, St George-Hyslop P, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Vardarajan BN, Vinters HV, Vonsattel JP, Wang LS, Weintraub S, Welsh-Bohmer KA, Williamson J, and Woltjer RL
- Subjects
- Aged, Alleles, Apolipoprotein E4 genetics, Autopsy, Female, Gene Dosage, Genetic Predisposition to Disease, Genotype, Humans, Linear Models, Male, Polymorphism, Single Nucleotide, RNA genetics, RNA isolation & purification, Risk Factors, Temporal Lobe metabolism, Alzheimer Disease genetics, Brain Chemistry genetics, Gene Expression physiology
- Abstract
Objective: Recent genome-wide association studies (GWAS) of late-onset Alzheimer disease (LOAD) identified 9 novel risk loci. Discovery of functional variants within genes at these loci is required to confirm their role in Alzheimer disease (AD). Single nucleotide polymorphisms that influence gene expression (eSNPs) constitute an important class of functional variants. We therefore investigated the influence of the novel LOAD risk loci on human brain gene expression., Methods: We measured gene expression levels in the cerebellum and temporal cortex of autopsied AD subjects and those with other brain pathologies (∼400 total subjects). To determine whether any of the novel LOAD risk variants are eSNPs, we tested their cis-association with expression of 6 nearby LOAD candidate genes detectable in human brain (ABCA7, BIN1, CLU, MS4A4A, MS4A6A, PICALM) and an additional 13 genes ±100 kb of these SNPs. To identify additional eSNPs that influence brain gene expression levels of the novel candidate LOAD genes, we identified SNPs ±100 kb of their location and tested for cis-associations., Results: CLU rs11136000 (p = 7.81 × 10(-4)) and MS4A4A rs2304933/rs2304935 (p = 1.48 × 10(-4)-1.86 × 10(-4)) significantly influence temporal cortex expression levels of these genes. The LOAD-protective CLU and risky MS4A4A locus alleles associate with higher brain levels of these genes. There are other cis-variants that significantly influence brain expression of CLU and ABCA7 (p = 4.01 × 10(-5)-9.09 × 10(-9)), some of which also associate with AD risk (p = 2.64 × 10(-2)-6.25 × 10(-5))., Conclusions: CLU and MS4A4A eSNPs may at least partly explain the LOAD risk association at these loci. CLU and ABCA7 may harbor additional strong eSNPs. These results have implications in the search for functional variants at the novel LOAD risk loci.
- Published
- 2012
- Full Text
- View/download PDF
18. Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation.
- Author
-
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappatà S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, and Puccio G
- Subjects
- Adult, Alzheimer Disease complications, Alzheimer Disease diagnostic imaging, Alzheimer Disease history, Brain diagnostic imaging, Brain pathology, Cognition Disorders etiology, Cognition Disorders genetics, Family Health, Female, Fluorodeoxyglucose F18, Gene Frequency, Genetic Predisposition to Disease, Genetic Testing, Genotype, Global Health, History, 17th Century, History, 21st Century, Humans, International Cooperation, Italy, Male, Memory Disorders etiology, Memory Disorders genetics, Middle Aged, Phenotype, Positron-Emission Tomography, Alzheimer Disease genetics, Leucine genetics, Methionine genetics, Mutation genetics, Presenilin-1 genetics
- Abstract
Objective: Large kindreds segregating familial Alzheimer disease (FAD) offer the opportunity of studying clinical variability as observed for presenilin 1 (PSEN1) mutations. Two early-onset FAD (EOFAD) Calabrian families with PSEN1 Met146Leu (ATG/CTG) mutation constitute a unique population descending from a remote common ancestor. Recently, several other EOFAD families with the same mutation have been described worldwide., Methods: We searched for a common founder of the PSEN1 Met146Leu mutation in families with different geographic origins by genealogic and molecular analyses. We also investigated the phenotypic variability at onset in a group of 50 patients (mean age at onset 40.0 +/- 4.8 years) by clinical, neuropsychological, and molecular methodologies., Results: EOFAD Met146Leu families from around the world resulted to be related and constitute a single kindred originating from Southern Italy before the 17th century. Phenotypic variability at onset is broad: 4 different clinical presentations may be recognized, 2 classic for AD (memory deficits and spatial and temporal disorientation), whereas the others are expressions of frontal impairment. The apathetic and dysexecutive subgroups could be related to orbital-medial prefrontal cortex and dorsolateral prefrontal cortex dysfunction., Conclusions: Genealogic and molecular findings provided evidence that the PSEN1 Met146Leu families from around the world analyzed in this study are related and represent a single kindred originating from Southern Italy. The marked phenotypic variability might reflect early involvement by the pathologic process of different cortical areas. Although the clinical phenotype is quite variable, the neuropathologic and biochemical characteristics of the lesions account for neurodegenerative processes unmistakably of Alzheimer nature.
- Published
- 2010
- Full Text
- View/download PDF
19. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation.
- Author
-
Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane F, Elder J, Kawarai T, Sato C, Pradella S, Wakutani Y, Anfossi M, Gallo M, Geracitano S, Costanzo A, Smirne N, Curcio SA, Mirabelli M, Puccio G, Colao R, Maletta RG, Kertesz A, St George-Hyslop P, Hardy J, and Rogaeva E
- Subjects
- Adult, Age of Onset, Aged, Aged, 80 and over, Chromosomes, Human, Pair 17 genetics, Cohort Studies, DNA Mutational Analysis, Dementia ethnology, Dementia metabolism, Female, Gene Frequency, Genetic Carrier Screening methods, Genetic Markers, Genetic Testing, Genotype, Heterozygote, Humans, Italy ethnology, Male, Middle Aged, Pedigree, Progranulins, Dementia genetics, Genetic Predisposition to Disease genetics, Intercellular Signaling Peptides and Proteins genetics, Mutation genetics
- Abstract
Background: Frontotemporal dementia (FTD) in several 17q21-linked families was recently explained by truncating mutations in the progranulin gene (GRN)., Objective: To determine the frequency of GRN mutations in a cohort of Caucasian patients with FTD without mutations in known FTD genes., Methods: GRN was sequenced in a series of 78 independent FTD patients including 23 familial subjects. A different Calabrian dataset (109 normal control subjects and 96 FTD patients) was used to establish the frequency of the GRN mutation., Results: A novel truncating GRN mutation (c.1145insA) was detected in a proband of an extended consanguineous Calabrian kindred. Segregation analysis of 70 family members revealed 19 heterozygous mutation carriers including 9 patients affected by FTD. The absence of homozygous carriers in a highly consanguineous kindred may indicate that the loss of both GRN alleles might lead to embryonic lethality. An extremely variable age at onset in the mutation carriers (more than five decades apart) is not explained by APOE genotypes or the H1/H2 MAPT haplotypes. Intriguingly, the mutation was excluded in four FTD patients belonging to branches with an autosomal dominant mode of inheritance of FTD, suggesting that another novel FTD gene accounts for the disease in the phenocopies. It is difficult to clinically distinguish phenocopies from GRN mutation carriers, except that language in mutation carriers was more severely compromised., Conclusion: The current results imply further genetic heterogeneity of frontotemporal dementia, as we detected only one GRN-linked family (about 1%). The value of discovering large kindred includes the possibility of a longitudinal study of GRN mutation carriers.
- Published
- 2007
- Full Text
- View/download PDF
20. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
- Author
-
Paisán-Ruíz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A, and Rogaeva E
- Subjects
- Adult, Age of Onset, Aged, Aged, 80 and over, Apolipoproteins E genetics, Case-Control Studies, DNA Mutational Analysis, Exons genetics, Family Health, Gene Frequency genetics, Genetic Testing, Genotype, Humans, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Middle Aged, Parkinson Disease metabolism, Polymorphism, Genetic genetics, Genetic Predisposition to Disease genetics, Mutation genetics, Parkinson Disease genetics, Protein Serine-Threonine Kinases genetics
- Abstract
Background: In addition to the four well-confirmed genes linked to early-onset Parkinson disease (PD) (SNCA, PARKIN, DJ-1, and PINK1), mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have recently been identified in families with autosomal dominant late-onset PD., Objective: To perform mutation analysis of LRRK2 in probands of families showing dominant inheritance of PD and to conduct a case control association study to test the hypothesis that common coding variations might be associated with increased susceptibility to PD., Methods: All 51 LRRK2 coding exons were sequenced in 23 probands and the mutation frequencies were evaluated in 180 neurologically normal control subjects. For the association study the authors genotyped four coding LRRK2 polymorphisms in 250 normal control subjects and 121 patients with PD (predominantly white patients of Canadian origin), 84% of whom had age at onset before 50 years and 42% had a positive family history., Results: The authors identified three probands with heterozygous LRRK2 mutations: two of them have the known G2019S substitution and one proband has a novel I1371V substitution. Mutation analysis of a large family demonstrated complete segregation of the G2019S with PD. However, there was no association between PD and any of the four polymorphisms at the allelic or genotypic levels (p > 0.17). Furthermore, the authors did not detect a modifying effect for any genotype or of APOE genotypes upon the age at onset in the PD group (p > 0.20)., Conclusions: The results support the prior suggestion that LRRK2 mutations cause PD. The disease in the families reported here presents a phenotype indistinguishable from typical PD. All three families demonstrate a very variable age at onset that is not explained by APOE genotypes. The common coding variations in the LRRK2 gene neither constitute strong PD risk factors nor modify the age at onset; however, the possibility of a modest risk effect remains to be assessed in large datasets.
- Published
- 2005
- Full Text
- View/download PDF
21. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.
- Author
-
Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, and Pollen DA
- Subjects
- Adult, Alzheimer Disease diagnosis, Brain pathology, Brain physiopathology, Cognition Disorders diagnosis, DNA Mutational Analysis, Disease Progression, Down-Regulation physiology, Family Health, Female, Genetic Predisposition to Disease genetics, Genetic Testing, Heterozygote, Humans, Male, Membrane Proteins genetics, Middle Aged, Mutation genetics, Predictive Value of Tests, Presenilin-1, tau Proteins cerebrospinal fluid, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease genetics, Amyloid beta-Peptides cerebrospinal fluid, Brain metabolism, Cognition Disorders cerebrospinal fluid, Cognition Disorders genetics, Peptide Fragments cerebrospinal fluid
- Abstract
CSF amyloid beta-peptide 42 (Abeta42) levels in presymptomatic subjects with pathogenic mutations in the PS1 gene are significantly lower than in an age-matched control group. Consequently, in these subjects, there is a window of opportunity estimated as at least 4 to 12 years to evaluate the ability of any putative prophylactic therapy to decrease, arrest, or reverse abnormalities in Abeta42 metabolism many years before clinical symptoms of Alzheimer disease are otherwise likely to occur.
- Published
- 2005
- Full Text
- View/download PDF
22. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation.
- Author
-
Edwards-Lee T, Ringman JM, Chung J, Werner J, Morgan A, St George Hyslop P, Thompson P, Dutton R, Mlikotic A, Rogaeva E, and Hardy J
- Subjects
- Adult, Age of Onset, Amino Acid Substitution, Female, Genes, Dominant, Humans, Male, Pedigree, Black or African American genetics, Amyloid beta-Protein Precursor genetics, Mutation, Missense, Point Mutation
- Abstract
The occurrence of an APP T174I mutation is described in a large American family of African descent with Alzheimer disease. The clinical characteristics were an unusually early onset of disease (early 30s), similar to a previously reported age at onset of this mutation in an Austrian family. Distinct from that family, seizures and myoclonus were prominent features of the disease in this kindred.
- Published
- 2005
- Full Text
- View/download PDF
23. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.
- Author
-
Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Richard E, Rogaev EI, Frommelt P, Sadovnick AD, Meschino W, Rockwood K, Boss MA, Mayeux R, and St George-Hyslop P
- Subjects
- Adult, Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Humans, Middle Aged, Presenilin-1, Referral and Consultation, Survival Analysis, Alzheimer Disease genetics, Genetic Testing methods, Membrane Proteins genetics, Mutation genetics
- Abstract
Background: Mutations in the presenilin-1 gene (PS1) account for a majority of patients with early-onset familial AD. However, the clinical indications and algorithms for genetic testing in dementia are still evolving., Methods: The entire open reading frame of the PS1 gene was sequenced in a series of 414 consecutive patients referred for diagnostic testing, including 372 patients with AD and 42 asymptomatic persons with a strong family history of AD., Results: Forty-eight independent patients screened had a PS1 mutation including 21 novel mutations. In addition, 3% of subjects (11/413) had a known polymorphism, the Glu318Gly substitution. The majority of the mutations were missense substitutions but there were three insertions and Delta exon 10 mutation. With six exceptions (codons 35, 178, 352, 354, 358, and 365) most of the mutations occurred at residues conserved in the homologous PS2 gene or in PS1 of other species., Conclusions: Eleven percent of a referral-based series of patients with AD can be explained by coding sequence mutations in the PS1 gene. The high frequency of PS1 mutations in this study indicates that screening for PS1 mutations in AD is likely to be successful, especially when directed at patients with a positive family history with onset before 60 years (90% of those with PS1 mutations were affected by age 60 years). This will also have significance for the secondary identification of at-risk relatives who might be candidates for future prophylactic therapies for AD.
- Published
- 2001
- Full Text
- View/download PDF
24. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype.
- Author
-
Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, and Hutton M
- Subjects
- Genotype, Haplotypes, Humans, Polymerase Chain Reaction, Neurodegenerative Diseases genetics, Neurodegenerative Diseases pathology, Supranuclear Palsy, Progressive genetics, Supranuclear Palsy, Progressive pathology, tau Proteins genetics
- Abstract
Objective: To analyze the association of polymorphisms in the tau gene with pathologically confirmed corticobasal degeneration (CBD)., Background: The authors previously described an extended tau haplotype (H1) that covers the human tau gene and is associated with the development of progressive supranuclear palsy (PSP). The authors now extend this analysis to CBD, a neurodegenerative condition with clinical and neuropathologic similarities to PSP. Like PSP, CBD is associated with accumulation of aggregates containing the 4-repeat isoforms of tau. Because of difficulty in diagnosis of CBD, the authors only analyzed cases with pathologically confirmed CBD., Methods: The authors collected 57 unrelated, neuropathologically confirmed cases of CBD. Tau sequencing in these cases failed to show the presence of pathogenic mutations. Polymorphisms that spanned the tau gene were analyzed in all CBD cases and controls., Results: Analyzing tau polymorphisms in CBD cases showed that the frequency of H1 and H1/H1 was significantly increased when analyzing all cases and when separating by country of origin. H1 frequency in all CBD cases was 0.921, compared with a control frequency of 0.766 (X(2) = 9.1, p = 0.00255 [1df], OR 3.56 [8.43 > CI 95% > 1.53]). The H1/H1 frequency was also significantly higher at 0.842 compared with 0.596 in age-matched controls (X(2) = 17.42, p = 0.00016, 2df), OR 3.61 [7.05 > CI 95% > 1.85])., Conclusions: The CBD tau association described here suggests that PSP and CBD share a similar cause, although the pathogenic mechanism behind the two diseases leads to a different clinical and pathologic phenotype.
- Published
- 2001
- Full Text
- View/download PDF
25. Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions.
- Author
-
Kertesz A, Kawarai T, Rogaeva E, St George-Hyslop P, Poorkaj P, Bird TD, and Munoz DG
- Subjects
- Adult, Humans, Immunohistochemistry, Male, Pedigree, Phenotype, Dementia genetics, Dementia pathology, Frontal Lobe pathology, Inclusion Bodies pathology, Temporal Lobe pathology, Ubiquitins analysis, tau Proteins analysis
- Abstract
Objective: To describe the clinical features, neuropathology, and genetic studies in a family with autosomal dominant frontotemporal dementia (FTD)., Background: Clinical Pick's disease, or FTD with parkinsonism, has been described in several families linked to chromosome 17 (FTDP-17). Most of these have shown tau protein mutations. The clinical and pathologic variations in these families resemble the spectrum of sporadic FTD or "Pick complex.", Methods: Clinical and behavioral analysis of the affected members with extensive histochemical and neuropathologic description of three cases, genetic analysis of three clinically affected members and seven at risk members to assess linkage to chromosome 17, and sequencing of the tau gene in two patients were performed., Results: The clinical pattern shows a highly stereotypic disinhibition dementia with late extrapyramidal features, progressive mutism, and terminal dysphagia in three generations of affected individuals. Neuropathology showed frontotemporal atrophy, and microscopically tau- and synuclein-negative and ubiquitin-positive neuronal inclusions, in the background of superficial cortical spongiosis, neuronal loss, and gliosis. Tau expression was restricted to oligodendroglia. All exons and surrounding introns of the tau gene were sequenced, and no mutation or disease-related polymorphisms were detected in either of two affected pedigree members., Conclusion: This family with autosomal dominant frontotemporal dementia (FTD) shows no tau expression in neurons. The ubiquitin-positive, tau-negative inclusions have been described before in FTD with and without motor neuron disease, but not in a familial form. The clinical and some pathologic features are similar to those of several of the families included in descriptions of FTD with parkinsonism linked to chromosome 17, but the linkage to tau has been excluded. The defect in this family, however, could be functionally related to tau mutations.
- Published
- 2000
- Full Text
- View/download PDF
26. A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics.
- Author
-
Harwood DG, Barker WW, Loewenstein DA, Ownby RL, St George-Hyslop P, Mullan M, and Duara R
- Subjects
- Aged, Aged, 80 and over, Alleles, Apolipoproteins E genetics, Female, Humans, Male, Odds Ratio, Risk Factors, Alzheimer Disease genetics, Ethnicity, Hispanic or Latino statistics & numerical data
- Abstract
Background: The prevalence of AD appears to vary widely in different ethnic groups. Certain risk factors for AD are well established for the general population, but there is little information regarding the relevance of these risk factors in specific ethnic groups., Objective: The authors examined the risk of AD associated with the APOE-epsilon4 allele, the APOE-epsilon2 allele, smoking, alcohol consumption, history of hypertension, low educational level, estrogen replacement therapy, and history of head trauma with loss of consciousness among samples of white non-Hispanics (WNH) (392 AD patients, 202 normal subjects) and white Hispanics (WHIS) (188 AD patients, 84 normal controls)., Design: This was a case-control study of patients evaluated at an outpatient memory disorders clinic and control subjects recruited from a free memory screening offered to the community., Results: Increased risk for AD was associated with the APOE-epsilon4 allele after controlling for age, education, and gender among WNH (OR = 3.5; 95% CI = 2.3 to 5.5) and WHIS (OR = 3.1; 95% CI = 1.7 to 5.8). No protective effect was conferred by the APOE-epsilon2 allele, although this relationship approached significance among WNH (p = 0.02). Low levels of education increased the risk for AD among WNH (OR = 3.1; 95% CI = 1.8 to 5.9) but not WHIS. Alcohol use and hypertension approached significance as risk factors in WNH (p < 0.05) but not WHIS. Estrogen replacement treatment approached significance as a protective factor in both ethnic groups (p < 0.05)., Conclusions: Although the APOE-epsilon4 allele is a risk factor for AD among WHIS and WNH, other risk factors such as low education and hypertension appear to be important only for WNH. Risk factors for AD reported or suggested previously that were not confirmed by this study include smoking and head trauma with loss of consciousness.
- Published
- 1999
- Full Text
- View/download PDF
27. Gerstmann-Sträussler-Scheinker disease with mutation at codon 102 and methionine at codon 129 of PRNP in previously unreported patients.
- Author
-
Young K, Jones CK, Piccardo P, Lazzarini A, Golbe LI, Zimmerman TR Jr, Dickson DW, McLachlan DC, St George-Hyslop P, and Lennox A
- Subjects
- Adult, Base Sequence, Codon, Female, Gerstmann-Straussler-Scheinker Disease pathology, Humans, Male, Middle Aged, Molecular Sequence Data, Gerstmann-Straussler-Scheinker Disease genetics, Methionine genetics, Mutation, Prions genetics
- Abstract
We present two patients with Gerstmann-Sträussler-Scheinker disease (GSS), one from a previously undescribed kindred and one from the Canadian branch of a previously reported British kindred. In both patients, GSS is caused by a substitution of thymine for cytosine at codon 102 of the prion protein gene (PRNP). In each patient, we confirmed the clinical diagnosis by neuropathologic examination. The mutation, causing a substitution of leucine for proline at residue 102 (P102L) of the prion protein, has been previously reported in at least 30 other families. In the patients described here, the mutation was in coupling with methionine at PRNP codon 129.
- Published
- 1995
- Full Text
- View/download PDF
28. Predictive testing for Wilson's disease using tightly linked and flanking DNA markers.
- Author
-
Farrer LA, Bowcock AM, Hebert JM, Bonné-Tamir B, Sternlieb I, Giagheddu M, St George-Hyslop P, Frydman M, Lössner J, and Demelia L
- Subjects
- Chromosome Mapping, Genotype, Hepatolenticular Degeneration diagnosis, Humans, Pedigree, Predictive Value of Tests, Prenatal Diagnosis, Genetic Linkage, Genetic Markers genetics, Hepatolenticular Degeneration genetics
- Abstract
We studied DNA polymorphisms for five new chromosome 13 markers in 52 Wilson's disease (WD) families from Europe, North America, and the Middle East. There was significant evidence for linkage between the Wilson's disease locus (WND) and all the marker loci. Multilocus linkage analysis, using a genetic linkage map established from reference pedigrees, suggested that WND is most likely between D13S31 and D13S59, at distances of 0.4 and 1.2 centimorgans, respectively. Our results suggest that the chromosomal location of the Wilson's disease gene is the same in all families from the populations studied. This evidence and the availability of many close, flanking, and polymorphic DNA markers make possible accurate and informative testing of potential carriers and WD homozygotes in families with at least one previously affected child. An advantage of a genetic linkage test over other laboratory methods for prediction of genotype in WD is that a reliable diagnosis can be made at a much earlier stage in life, including prenatally. In addition, DNA testing can be used in place of an invasive liver biopsy procedure to confirm a diagnosis in patients with borderline serum ceruloplasmin levels. Presymptomatic identification will also allow therapeutic intervention to prevent symptoms before irreparable liver or neurologic damage occurs. We describe the implementation of prenatal and preclinical diagnosis for two families with WD.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.